Assessment of therapeutic response in patients with metastatic bone disease.
Affiliation
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.Issue Date
2004-10
Metadata
Show full item recordAbstract
Metastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.Citation
Assessment of therapeutic response in patients with metastatic bone disease. 2004, 5 (10):607-16 Lancet Oncol.Journal
The Lancet OncologyDOI
10.1016/S1470-2045(04)01596-7PubMed ID
15465464Type
ArticleLanguage
enISSN
1470-2045ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(04)01596-7